Combo of Roche's Tecentriq and Exelixis' Cabometyx fails another trial, this time in lung cancer

Combo of Roche's Tecentriq and Exelixis' Cabometyx fails another trial, this time in lung cancer

Source: 
Fierce Pharma
snippet: 

A fresh flop in metastatic non-small cell lung cancer (NSCLC) marks the latest in a string of clinical losses for the pairing of Exelixis and Ipsen's tyrosine kinase inhibitor Cabometyx and Roche’s immuno-oncology star Tecentriq.